keyword
MENU ▼
Read by QxMD icon Read
search

corticosteroid alopecia areata

keyword
https://www.readbyqxmd.com/read/28598005/higher-concentrations-of-dithranol-appear-to-induce-hair-growth-even-in-severe-alopecia-areata
#1
M R Ngwanya, N A Gray, F Gumedze, A Ndyenga, N P Khumalo
Alopecia areata (AA) is the commonest autoimmune cause of non-scarring alopecia. Topical treatments including corticosteroids and irritants maybe beneficial. Studies report variable hair regrowth with dithranol (anthralin) but all used low concentrations (0.1-1.25%) and inconsistent measurements of AA severity. We report retrospective data (2005-2014) of 102 patients who had failed ultra-potent topical steroids and were referred to a specialist hair clinic for treatment with dithranol up to 3%. The severity of alopecia areata tool was used and participants graded as mild (<25%), moderate (>25 to 75%), and severe (>75%) hair loss...
June 9, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28555441/alopecia-areata-of-the-beard-a-review-of-the-literature
#2
REVIEW
Jessica Cervantes, Raymond M Fertig, Austin Maddy, Antonella Tosti
Alopecia areata (AA) is a T-cell mediated autoimmune disorder in which inflammatory cells attack the hair follicle, resulting in round, well-circumscribed patches of noncicatricial hair loss in normal appearing skin. AA affecting the beard area is well known and is referred to as AA of the beard (BAA) or AA barbae when involvement is limited exclusively to the beard. BAA has been documented in a select number of studies. We review the literature and discuss the clinical features, epidemiology, diagnosis, and treatment of BAA...
May 29, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28489468/best-dilution-of-the-best-corticosteroid-for-intralesional-injection-in-the-treatment-of-localized-alopecia-areata-in-adults
#3
Pelin Ustuner, Ali Balevi, Mustafa Özdemir
PURPOSE: To evaluate and compare the clinical efficacy, dermoscopic results and safety of triamcinolone acetonide (TA) and betamethasone dipropionate (BD) injections at different concentrations in localized scalp and beard alopecia. METHODS: Intralesional injection of BD or TA in three different dilutions; 1/4, 1/8, 1/12 (BD1, BD2, BD3, TA1, TA2, TA3) and Saline (control) was randomly applied to a total of 231 alopecia patches in 83 patients every four weeks in a maximum of six sessions until a hair regrowth score of 4 was achieved...
May 30, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28487843/anaphylaxis-following-intralesional-triamcinolone-acetonide-kenacort-injection
#4
Wannada Laisuan, Chamard Wongsa, Nizchapha Dchapaphapeaktak, Malinee Tongdee, Jidapa Chatmapanrangsee, Ticha Rerkpattanapipat
Intralesional triamcinolone acetonide injection is indicated for multiple skin conditions such as keloid scars, alopecia areata, and hypertrophic lichen planus. Immediate hypersensitivity reaction remains uncommon. We report on a 24-year-old woman who had received multiple intralesional injections with triamcinolone acetonide (Kenacort) plus lidocaine for keloid scar treatment without any reaction for the previous 10 years. The immediate reaction occurred 15 minutes after injection, with numbness on her face and 5 minutes later with urticaria on her chest wall and upper extremities, together with hypotension (blood pressure of 90/60 mmHg)...
April 2017: Asia Pacific Allergy
https://www.readbyqxmd.com/read/28442879/methotrexate-in-alopecia-areata-a-report-of-three-cases
#5
Ana Batalla, Ángeles Flórez, Teresa Abalde, Hugo Vázquez-Veiga
There are few studies about systemic treatment in severe cases of alopecia areata (AA), especially in the pediatric population. Although there is more experience with systemic corticosteroids, recent reports have suggested methotrexate (MTX) as an alternative treatment, with a relatively good outcome. We describe three cases of AA in children treated with MTX, two of them with successful results.
October 2016: International Journal of Trichology
https://www.readbyqxmd.com/read/28426924/high-dose-pulsed-corticosteroid-therapy-combined-with-methotrexate-for-severe-alopecia-areata-of-childhood
#6
LETTER
J H Chong, A Taïeb, F Morice-Picard, A S Dutkiewicz, C Léauté-Labrèze, F Boralevi
No abstract text is available yet for this article.
April 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28329619/bitemporal-hair-loss-related-to-traction-alopecia
#7
Oscar Muñoz Moreno-Arrones, Sergio Vañó-Galván
We present a 24-year-old woman that had received a diagnosis of alopecia areata in the past and was treated with topical 19 corticosteroids with little improvement. Instead, the patient exhibited bitemporal alopecia of one year of evolution related to 20 traction alopecia. Traction alopecia is characterized by localized hair loss related to persistent excessive traction. Although it is 21 initially a reversible condition, if this excessive traction is not removed permanent alopecia may develop.
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28140540/sequential-high-and-low-dose-systemic-corticosteroid-therapy-for-severe-childhood-alopecia-areata
#8
Karin Jahn-Bassler, Wolfgang Michael Bauer, Franz Karlhofer, Matthias G Vossen, Georg Stingl
BACKGROUND: Given the limited number of therapeutic options, severe childhood alopecia areata (AA) poses a clinical challenge. The best and most rapid response rates can be achieved with high-dose systemic corticosteroids, however, relapse following treatment discontinuation is inevitable. Due to systemic side effects, long-term high-dose corticosteroid regimens are not feasible. Following initial pulse therapy, continuation of corticosteroid therapy at a dose below the Cushing threshold might be able to suppress disease activity without causing severe side effects...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28101018/remarkable-improvement-of-nail-changes-in-alopecia-areata-universalis-with-10-months-of-treatment-with-tofacitinib-a-case-report
#9
Sineida Berbert Ferreira, Morton Scheinberg, Denise Steiner, Tatiana Steiner, Gustavo Longhi Bedin, Rachel Berbert Ferreira
Alopecia areata (AA) is a chronic, autoimmune disease. The main symptom is massive hair loss, localized or diffuse, in the scalp and the whole body. However, nails may also be involved, and brittleness, fragility and pitting can be signs of nail dystrophy in AA patients. Here, we report the case of a male patient with AA refractory to various treatments, including oral, topical and intralesional corticosteroids, immunosuppressants, cyclosporin and PUVA (oxoralen plus ultraviolet light), all interrupted due to side effects...
September 2016: Case Reports in Dermatology
https://www.readbyqxmd.com/read/27871349/alopecia-areata-part-iii-prognosis-and-treatment
#10
Juliany Estefan, Marcia Ribeiro, Eliane Abad, Simone Saintive, Marcia Ramos-E-Silva
The prognosis of alopecia areata is better in cases with single and small lesions, and the variability of the extension of the disease is one of the criteria for the choice of treatment modality. Several medications have been described in the literature for the treatment of alopecia areata, including corticosteroids, minoxidil, and diphencyprone. The authors review treatments for alopecia areata.
2016: Skinmed
https://www.readbyqxmd.com/read/27802065/a-review-on-laser-and-light-based-therapies-for-alopecia-areata
#11
Stephanie Mlacker, Adam Souhail Aldahan, Brian James Simmons, Vidhi Shah, Colin Andrew McNamara, Sahal Samarkandy, Keyvan Nouri
Alopecia areata is a form of non-scarring alopecia that results from a hyperactive immune response of T cells against hair follicles. Many patients with visible hair loss experience psychological and emotional distress, as a result of their cosmetic disfigurement, and frequently seek treatment. However, existing treatment methods, such as corticosteroids, topical irritants, sensitizing agents, immunosuppressants, and psoralen plus ultraviolet light A, may result in various adverse effects and often lack efficacy...
April 2017: Journal of Cosmetic and Laser Therapy: Official Publication of the European Society for Laser Dermatology
https://www.readbyqxmd.com/read/27770310/treating-alopecia-areata-current-practices-versus-new-directions
#12
REVIEW
Aditya K Gupta, Jessie Carviel, William Abramovits
Alopecia areata (AA) is non-scarring hair loss resulting from an autoimmune disorder. Severity varies from patchy hair loss that often spontaneously resolves to severe and chronic cases that can progress to total loss of scalp and body hair. Many treatments are available; however, the efficacy of these treatments has not been confirmed, especially in severe cases, and relapse rates are high. First-line treatment often includes corticosteroids such as intralesional or topical steroids for mild cases and systemic steroids or topical immunotherapy with diphenylcyclopropenone or squaric acid dibutylester in severe cases...
February 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/27546732/cd8-mycosis-fungoides-clinically-masquerading-as-alopecia-areata
#13
Sapna M Amin, Timothy Tan, Joan Guitart, Maria Colavincenzo, Pedram Gerami, Pedram Yazdan
A 33-year-old female with a 7-year history of CD8-positive hypopigmented mycosis fungoides (MF) involving the trunk and extremities presented with a large well-defined alopecic patch on her frontal scalp. Clinically, this area resembled alopecia areata (AA) and was without hypopigmentation or erythema. A scalp biopsy revealed a non-scarring inflammatory alopecia and a superficial band-like atypical lymphoid infiltrate with prominent epidermotropism. Atypical, predominately CD8-positive lymphocytes were seen surrounding and infiltrating the bulb portion of several hair follicles...
December 2016: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/27516698/the-most-frequent-herbs-proposed-by-iranian-traditional-medicine-for-alopecia-areata
#14
Maedeh Rezghi, Shirin Fahimi, Sara Zakerin
BACKGROUND: Alopecia areata (AA) is a common immune-mediated hair loss disorder. AA has a reported incidence of 0.1-0.2% with a lifetime risk of 1.7%. Histologically, AA is characterized by the accumulation of mononuclear cells around the bulb of the affected hair follicles. Corticosteroids are the most popular drugs for the treatment of this disease. Despite its high prevalence, currently available treatments are mostly unsatisfactory and inefficient for the more chronic and severe types of the AA...
May 2016: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/27498663/successful-treatment-of-alopecia-areata-with-dr-michaels%C3%A2-alopinex-product-family
#15
U Wollina, J Hercogovấ, M Fioranelli, S Gianfaldoni, A A Chokoeva, G Tchernev, M Tirant, F Novotny, M G Roccia, G K Maximov, K França, T Lotti
UNLABELLED: Alopecia areata is a highly prevalent organ restricted autoimmune disorder that leads to disfiguring hair loss and is thought to involve a T cell–mediated response to the hair follicle. The treatment of alopecia areata is often problematic and very frustrating, partly due to the unknown aetiology of the condition. The aim of this study was to evaluate the efficacy and tolerability of complementary medicine, Dr. Michaels® product family, in the treatment of alopecia areata...
April 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/27448451/intramuscular-triamcinolone-acetonide-an-undervalued-option-for-refractory-alopecia-areata
#16
Jimyung Seo, Young In Lee, Shinwon Hwang, Zhenlong Zheng, Do Young Kim
Severe alopecia areata (AA) can have an unpredictable clinical course and become refractory to contact immunotherapy. Novel treatment options include low-dose interleukin-2 and Janus kinase inhibitors; however, these treatments are still under investigation. Therefore, we evaluated the efficacy and safety of intramuscular (i.m.) triamcinolone acetonide (TAC) as a rescue therapy for refractory AA. We retrospectively analysed efficacy, adverse effects and relapse rate of i.m. TAC monthly in 27 patients with refractory AA...
February 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/27377163/successful-treatment-of-pediatric-alopecia-areata-of-the-scalp-using-topical-bimatoprost
#17
Alvin W Li, Richard J Antaya
Alopecia areata (AA) is a genetic and immune-mediated disease that targets anagen hair follicles. Despite limited evidence supporting the efficacy of corticosteroid treatments, they are often prescribed as first-line therapy because of their favorable safety profile. Prostaglandin analogues are currently being studied as an alternate therapy for scalp AA in adults. Herein we present a case of steroid-resistant multifocal AA that was successfully treated with topical bimatoprost.
September 2016: Pediatric Dermatology
https://www.readbyqxmd.com/read/27191524/understanding-autoimmunity-of-vitiligo-and-alopecia-areata
#18
Jillian F Rork, Mehdi Rashighi, John E Harris
PURPOSE OF REVIEW: Vitiligo and alopecia areata are common, disfiguring skin diseases. Treatment options are limited and include nontargeted approaches, such as corticosteroids, topical calcineurin inhibitors, narrow band ultraviolet B phototherapy, and other immune-modifying agents. The purpose of this article is to review shared, novel mechanisms between vitiligo and alopecia areata, as well as discuss how they inform the development of future targeted treatments. RECENT FINDINGS: Vitiligo and alopecia areata are both autoimmune diseases, and striking similarities in pathogenesis have been identified at the level of both the innate and adaptive immune system...
August 2016: Current Opinion in Pediatrics
https://www.readbyqxmd.com/read/27095016/multiple-courses-of-pulse-corticosteroid-therapy-for-alopecia-areata
#19
Takashi Yoshimasu, Nobuo Kanazawa, Yuki Yamamoto, Fukumi Furukawa
Various systemic corticosteroid therapies are used for alopecia areata (AA). Pulse therapy using methylprednisolone is a treatment approach for AA. The efficacy of multiple courses of pulse therapy for various severities of AA was evaluated. AA patients with less than 50% hair loss, less than or equal to 6 months after AA onset, needed 1.9 courses of pulse therapy for vellus hair to develop. On the other hand, AA patients with more than 50% hair loss, less than 6 months after AA onset, needed more courses of pulse therapy for vellus hair to develop...
September 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27051761/successful-treatment-of-corticosteroid-resistant-ophiasis-type-alopecia-areata-aa-with-platelet-rich-plasma-prp
#20
Jeff Donovan
No abstract text is available yet for this article.
September 2015: JAAD Case Reports
keyword
keyword
98722
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"